Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02453282) enrolled 1,118 people with lung cancer across three groups: 374 received durvalumab alone, 372 received durvalumab combined with tremelimumab, and 372 received standard chemotherapy. The trial was primarily measuring two things: how long participants lived overall (called "overall survival"), and how long they went without their disease getting worse (called "progression-free survival"), focusing especially on participants whose tumours had a certain level of a protein marker called PD-L1. The reported data shows that, among participants with higher PD-L1 levels (at least 25% of tumour cells testing positive), the median overall survival — that is, the midpoint time at which half the participants in each group had died — was 16.3 months for the durvalumab-alone group, 11.9 months for the durvalumab-plus-tremelimumab group, and 12.9 months for the standard chemotherapy group. For progression-free survival in that same higher PD-L1 group, the reported median was 3.9 months for the combination group compared with 5.4 months for chemotherapy. When looking at the full study population regardless of PD-L1 levels, the reported median overall survival figures were 12.3 months, 11.2 months, and 11.8 months for the three groups respectively. The reported data also notes that no participants were recorded as having "completed" the study, meaning all participants either stopped early or were still being followed at the time the data was recorded. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Active, Not Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must be at least 18 years old.
- You must have been diagnosed with a specific advanced form of lung cancer called Stage IV non-small cell lung cancer (NSCLC).
- Your lung cancer must not have certain specific gene changes (known as EGFR mutation or ALK rearrangement) based on test results.
- You must not have had any chemotherapy or other cancer-fighting medicines for your lung cancer that has spread or come back.
- You must be fairly well and active in daily life, rated as 0 or 1 on a standard health scale used by doctors (meaning you are either fully active or able to do light activities).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is a mixed type combining small-cell lung cancer with non-small cell lung cancer, or a specific rare type called sarcomatoid (confirm with trial site).
- People who have cancer that has spread to the brain or spine, unless it has already been treated, is stable, and does not require steroid medication.
- People who have previously received certain types of cancer immunotherapy treatments that target the immune system (such as anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 medicines), though cancer vaccines are not included in this restriction.
- People who have or have previously had conditions where the immune system attacks the body, such as inflammatory bowel disease, Crohn's disease, or colitis.
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy; Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
Other options
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.